Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2013 Nov 21

PMID 24253260

Citations 22

Authors

Erica B Schleifman

Nicole Ali McNeer

Andrew Jackson

Jennifer Yamtich

Michael A Brehm

Leonard D Shultz

Dale L Greiner

Priti Kumar

W Mark Saltzman

Peter M Glazer

Affiliations

Soon will be listed here.

Abstract

Biodegradable poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating triplex-forming peptide nucleic acids (PNAs) and donor DNAs for recombination-mediated editing of the CCR5 gene were synthesized for delivery into human peripheral blood mononuclear cells (PBMCs). NPs containing the CCR5-targeting molecules efficiently entered PBMCs with low cytotoxicity. Deep sequencing revealed that a single treatment with the formulation resulted in a targeting frequency of 0.97% in the CCR5 gene and a low off-target frequency of 0.004% in the CCR2 gene, a 216-fold difference. NP-treated PBMCs efficiently engrafted immunodeficient NOD-scid IL-2rγ(-/-) mice, and the targeted CCR5 modification was detected in splenic lymphocytes 4 weeks posttransplantation. After infection with an R5-tropic strain of HIV-1, humanized mice with CCR5-NP-treated PBMCs displayed significantly higher levels of CD4(+) T cells and significantly reduced plasma viral RNA loads compared with control mice engrafted with mock-treated PBMCs. This work demonstrates the feasibility of PLGA-NP-encapsulated PNA-based gene-editing molecules for the targeted modification of CCR5 in human PBMCs as a platform for conferring HIV-1 resistance.Molecular Therapy-Nucleic Acids (2013) 2, e135; doi:10.1038/mtna.2013.59; published online 19 November 2013.

Citing Articles

Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization.

Vasukutty A, Jang Y, Han D, Park H, Park I Biomater Res. 2024; 28:0078.

PMID: 39416703 PMC: 11480834. DOI: 10.34133/bmr.0078.

Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation.

Gupta A, Barone C, Quijano E, Piotrowski-Daspit A, Perera J, Riccardi A J Cyst Fibros. 2024; 24(1):142-148.

PMID: 39107154 PMC: 11788067. DOI: 10.1016/j.jcf.2024.07.009.

DNA recognition and induced genome modification by a hydroxymethyl-γ tail-clamp peptide nucleic acid.

Oyaghire S, Quijano E, Perera J, Mandl H, Saltzman W, Bahal R Cell Rep Phys Sci. 2023; 4(10).

PMID: 37920723 PMC: 10621889. DOI: 10.1016/j.xcrp.2023.101635.

Cationic Calix[4]arene Vectors to Efficiently Deliver AntimiRNA Peptide Nucleic Acids (PNAs) and miRNA Mimics.

Gasparello J, Papi C, Zurlo M, Volpi S, Gambari R, Corradini R Pharmaceutics. 2023; 15(8).

PMID: 37631335 PMC: 10460053. DOI: 10.3390/pharmaceutics15082121.

In vivo correction of cystic fibrosis mediated by PNA nanoparticles.

Piotrowski-Daspit A, Barone C, Lin C, Deng Y, Wu D, Binns T Sci Adv. 2022; 8(40):eabo0522.

PMID: 36197984 PMC: 9534507. DOI: 10.1126/sciadv.abo0522.

References

Park M, Chung S, Park Y, Lee S . Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine. 2008; 76(2):170-5. DOI: 10.1016/j.jbspin.2008.04.018. View

Schleifman E, Bindra R, Leif J, del Campo J, Rogers F, Uchil P . Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem Biol. 2011; 18(9):1189-98. PMC: 3183429. DOI: 10.1016/j.chembiol.2011.07.010. View

Zhou J, Patel T, Fu M, Bertram J, Saltzman W . Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials. 2011; 33(2):583-91. PMC: 4204797. DOI: 10.1016/j.biomaterials.2011.09.061. View

Jain A, Bacolla A, Chakraborty P, Grosse F, Vasquez K . Human DHX9 helicase unwinds triple-helical DNA structures. Biochemistry. 2010; 49(33):6992-9. PMC: 2949957. DOI: 10.1021/bi100795m. View

Allain J, Laurian Y, Paul D, Verroust F, Leuther M, Gazengel C . Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med. 1987; 317(18):1114-21. DOI: 10.1056/NEJM198710293171804. View

Samson M, Libert F, Doranz B, Rucker J, Liesnard C, Farber C . Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996; 382(6593):722-5. DOI: 10.1038/382722a0. View

Lucotte G . Frequencies of 32 base pair deletion of the (Delta 32) allele of the CCR5 HIV-1 co-receptor gene in Caucasians: a comparative analysis. Infect Genet Evol. 2003; 1(3):201-5. DOI: 10.1016/s1567-1348(02)00027-8. View

Rogers F, Vasquez K, Egholm M, Glazer P . Site-directed recombination via bifunctional PNA-DNA conjugates. Proc Natl Acad Sci U S A. 2002; 99(26):16695-700. PMC: 139206. DOI: 10.1073/pnas.262556899. View

OBrien S, Nelson G . Human genes that limit AIDS. Nat Genet. 2004; 36(6):565-74. DOI: 10.1038/ng1369. View

10.

Mcneer N, Chin J, Schleifman E, Fields R, Glazer P, Saltzman W . Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther. 2010; 19(1):172-80. PMC: 3017438. DOI: 10.1038/mt.2010.200. View

11.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

12.

Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E . Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2010; 117(10):2791-9. DOI: 10.1182/blood-2010-09-309591. View

13.

Maurisse R, de Semir D, Emamekhoo H, Bedayat B, Abdolmohammadi A, Parsi H . Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol. 2010; 10:9. PMC: 2830169. DOI: 10.1186/1472-6750-10-9. View

14.

Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S . Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med. 2001; 135(9):782-95. DOI: 10.7326/0003-4819-135-9-200111060-00008. View

15.

Cheng C, Saltzman W . Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials. 2011; 32(26):6194-203. PMC: 3130098. DOI: 10.1016/j.biomaterials.2011.04.053. View

16.

Perez E, Wang J, Miller J, Jouvenot Y, Kim K, Liu O . Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008; 26(7):808-16. PMC: 3422503. DOI: 10.1038/nbt1410. View

17.

Papapetrou E, Zoumbos N, Athanassiadou A . Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Ther. 2005; 12 Suppl 1:S118-30. DOI: 10.1038/sj.gt.3302626. View

18.

Bashir A, Volik S, Collins C, Bafna V, Raphael B . Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput Biol. 2008; 4(4):e1000051. PMC: 2278375. DOI: 10.1371/journal.pcbi.1000051. View

19.

Visscher G, Robison R, Maulding H, Fong J, Pearson J, Argentieri G . Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res. 1985; 19(3):349-65. DOI: 10.1002/jbm.820190315. View

20.

Kopel V, Pozner A, Baran N, Manor H . Unwinding of the third strand of a DNA triple helix, a novel activity of the SV40 large T-antigen helicase. Nucleic Acids Res. 1996; 24(2):330-5. PMC: 145642. DOI: 10.1093/nar/24.2.330. View